Merit Medical Reports Third Quarter 2026 Results: Delivers 9% Organic Constant Currency Revenue Growth and Raises Full-Year 2026 Guidance
Merit Medical reported Q3 2026 revenue of $416.2 million, up 8.4% year-over-year, with 9% organic constant currency growth that management said exceeded the high end of its expectations. Profitability improved sharply: GAAP operating margin expanded to 14.1% from 11.1%, GAAP EPS rose 51% to $0.70, and non-GAAP EPS rose 22% to $1.12. The company raised full-year 2026 guidance, narrowing revenue to $1.635-$1.642 billion and lifting non-GAAP EPS to $4.33-$4.37 from the prior $4.25-$4.35 range.
Key figures
- Eps
- 0.7
- Revenue
- 416244000
- Guidance
- FY26 revenue $1.635-$1.642 billion (8% Y/Y); non-GAAP EPS $4.33-$4.37 (13%-14% Y/Y), raised from $1.631-$1.643 billion and $4.25-$4.35
- Revenue Yoy
- 8.4%
- Cash
- 503551000
- Fcf ytd
- 129544000
- Total debt
- 747500000
- Gaap eps yoy
- 51%
- Non gaap eps
- 1.12
- Gaap net income
- 42311000
- Non gaap eps yoy
- 22%
- Gaap operating margin
- 14.1%
- Operating cash flow ytd
- 175230000
- Non gaap operating margin
- 21.3%
- Organic cc revenue growth
- 9%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.